OARS funding Cancer

The FY19 PRCRP Horizon Award supports junior-level scientists in conducting impactful research with the mentorship of an experienced cancer researcher (i.e., Mentor). The intent of the Horizon Award is to recruit junior-level scientists to perform research in one of the FY19 PRCRP Topic Areas. The Horizon Award challenges junior scientists to develop and implement research in the cancer field. This opportunity allows for junior investigators to develop a research project, investigate a problem or question in the field of cancer, and further their intellectual development as a cancer researcher of the future. Under this award mechanism, the junior investigator is considered the Principal Investigator (PI), and the application should focus on the PI's research and career development. It should be clear that the proposed research is intellectually designed by the PI with assistance from the Mentor. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated. Clinical trials will not be supported by this mechanism.

The FY19 PRCRP Idea Award with Special Focus supports innovative, untested, high-risk/ potentially high-reward concepts, theories, paradigms, and/or methods in cancer research that are relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. The "Special Focus" of this award mechanism is on exposures, conditions, or circumstances that are unique to the military, disproportionately represented in a military beneficiary population, or may affect force readiness. Cancers or circumstances with cancer risk that may affect the Service members' support system (military families) are of special importance for total mission readiness. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System (MHS) is critical to active duty Service members, Veterans, other military beneficiaries, and the American public. Relevance to military health should be articulated with respect to the overall MHS, the FY19 PRCRP Military Health Focus Areas in Section II.A.2, and the mission of the DHP and the FY19 PRCRP.

The FY19 PRCRP Impact Award supports hypothesis-driven, high-impact research. The Impact Award mechanism encourages applications with mature research projects that specifically focus on critical scientific or clinical cancer issues, which, if successfully addressed, have the potential to make a major impact on at least one of the FY19 PRCRP Topic Areas. Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples and trials. Through the Impact Award, the PRCRP seeks to build foundations for finding cures in under-funded, under-studied, and/or lethal militarily relevant cancer or research areas. With the Impact Award, PRCRP offers the unique opportunity to find commonalities in research across multiple cancers that advance the broader cancer field and to address cancer funding disparities within the FY19 PRCRP Topic Areas. The Impact Award supports identifying scientific outcomes through rigorous, robust research that are translatable toward treatment and/or preventive strategies. Research proposed should aim to accelerate promising findings toward clinical applicability and leverage research results to maximize impact.

The FY19 PRCRP Translational Team Science Award (TTSA) supports hypothesis-driven translational studies. These studies should be associated with a clinical trial. The proposed project should focus on research for the next-phase clinical trial or future clinical application. The TTSA is intended to support advanced translational studies that are based on results from clinical investigations. While funding for clinical trials is allowed, the TTSA is intended to support multi-investigator, multidisciplinary teams to perform clinical research studies and not only to fund a clinical trial. Research projects funded by the TTSA should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or investigate novel clinical findings. New for FY19: The FY19 PRCRP TTSA Areas of Emphasis (strongly encouraged but not required): · Interventions to improve quality of life for cancer patients and/or survivors · Cancer prevention or early detection · Understanding metastatic disease to improve outcomes

The FY19 PRCRP Career Development Award supports independent, early-career investigators to conduct impactful research with the guidance of an experienced cancer researcher (i.e., Career Guide). The Career Development Award presents an opportunity for early-career investigators to obtain the funding, guidance, and experience necessary for productive, independent careers at the forefront of cancer research. This award supports impactful research projects with an emphasis on discovery. Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PI's research and career development. It should be clear that the proposed research is intellectually designed by the PI and not a product of the Career Guide. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.

The purpose of this Funding Opportunity Announcement (FOA) is to support the planning and development of translational research programs focused upon cancer health disparities research. The P20 grants supported by this FOA are expected to expand into comprehensive translational research programs focused upon cancer health disparities and ultimately compete for P50 awards under the umbrella of the National Cancer Institute (NCI) "Specialized Programs of Research Excellence (SPOREs)". Each P20 Program proposed must include the following components: Research Program (at least two translational research projects are required); Administrative Core; Shared Resource Facility (Biospecimen/Pathology Core is required); and Developmental Research Program. The research supported through the P20 Program must be translational in nature and must focus upon knowledge of human biology with a translational human endpoint proposed. The proposed research theme for the P20 Program must be focused on addressing disparities in cancer incidence, prevalence, mortality, survivorship, and/or burden of cancer, or related health conditions, that are well documented among racial/ethnic minority populations. Projects may focus on a wide range of research areas including prevention, early detection, diagnosis, treatment, epidemiology and/or cancer control, and are expected to have clear translational potential to advance research findings to applications relevant for clinical practice and/or healthcare settings.

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) and VentureWell have come together to support and expand DEBUT, a competition that recognizes undergraduate excellence in biomedical design and innovation. DEBUT challenges teams of students in undergraduate biomedical education to solve real-world problems in healthcare. Prizes of up to $20,000 will be awarded. Strong DEBUT submissions will demonstrate a mastery of analytical and design skills and capabilities; the ability to manage the product development process; the ability to work effectively in teams; and technical communication skills. Submissions will be judged on the following criteria: Significance of the problem being addressed Impact of the proposed solution on potential users and clinical care Innovative design Working prototype Additional prizes will be awarded to entries that also demonstrate: Market potential and economic feasibility Patentability

The world needs more effective, functional and affordable technology solutions to clinical medical problems. With the BMEidea competition, the nation's leading competition for biomedical and bioengineering students, we challenge students to pioneer a health-related technology that addresses a real clinical need. Competition entries are judged on: Technical, economic and regulatory feasibility Contribution to human health and quality of life Technological innovation Potential for commercialization Strong BMEidea submissions define a problem and demonstrate the development of a device, product, or technology designed to solve it. BMEidea awards are presented each year at the MD&M East Medical Device Trade Show and Convention. Competition winners will receive cash awards as well as access to resources to be used for further development and commercialization of their products. In addition, the first place institution will get to display the BMEidea trophy in their winning department for the year.

This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. Furthermore, all research projects must be focused upon knowledge of human biology with a translational human endpoint proposed. All P20 grants must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees

Eliminate Cancer Will you be the one in three women diagnosed with some form of cancer during your lifetime? If not, you will likely know her. She may be your friend, neighbor, mother, sister or even your daughter. With your support, The Mary Kay Foundation is dedicated to eliminating cancers affecting women. End Domestic Violence Home should be a safe haven. Unfortunately, the homes of thousands of women and children are plagued by domestic violence. With your help, The Mary Kay Foundation is committed to stopping the violence, breaking the silence and making a difference for these women and children.

NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. (https://www.ds-pharma.com/) ("Client"), seeks a technology platform to discover synthetic lethal factors that can serve as the target for drug discovery. The Client has advantages in cancer research. Through cooperation with the proposer, they aim at discovering a novel synthetic lethal factor(s) using proposer's technology platform and finally creating innovative next-generation molecularly targeted anti-cancer drugs. In addition to proposals on technology platform, this RFP also welcomes those on novel synthetic lethal factors discovered using the technology platform.

NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. (https://www.ds-pharma.com/) ("Client"), seeks a drug modality for novel anti-cancer drugs that target immunosuppressive cells and interfere with immune functions, or an evaluation system for creating a drug modality. In recent years, the emergence of immune checkpoint inhibitors has been gradually revealing that the local immunosuppressive environment in tumor affects cancer treatment. This attracts interest in the development of novel antitumor drugs for improving the immune state of the tumor microenvironment. In particular, we look for compounds that target host cells contributing to the formation of the immunosuppressive environment and interfering with these functions. Focusing on cancer as its key area and considering the development of novel unique products to be its basic strategy, the Client decided to seek a partner with whom it can provide novel drugs to the market as soon as possible based on the above concept.

NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. (https://www.ds-pharma.com/ ) (the "Client"), seeks a partner that wishes to make use of (i.e. technology assessment / licensing-in) an antibody-drug conjugate (ADC) technology developed by the Client called antibody intracellular activated drug conjugate (AiADC) technology. The Client aims to bring innovative anti-cancer drugs to the market by developing ADC technology that can be used generously for various antibodies. The Client has already succeeded in developing AiADC technology, which is more effective and safer than conventional ADC technologies. They believe that the innovative technology can make a new solution in cancer treatment. They seek to make the technology applicable to a wider range of antibodies. With an aim to accelerate drug discovery based on its AiADC technology, the Client has decided to make this RFP to broaden the potential of this proprietary technology through partnership with a company that possesses promising antibody seeds.

NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. (https://www.ds-pharma.com/) ("Client"), seeks a drug modality for novel anti-cancer drugs that target immunosuppressive cells and interfere with immune functions, or an evaluation system for creating a drug modality. In recent years, the emergence of immune checkpoint inhibitors has been gradually revealing that the local immunosuppressive environment in tumor affects cancer treatment. This attracts interest in the development of novel antitumor drugs for improving the immune state of the tumor microenvironment. In particular, we look for compounds that target host cells contributing to the formation of the immunosuppressive environment and interfering with these functions.

Founded in 2009 by two sisters from Brooklyn, the Tell Every Amazing Lady (T.E.A.L.) About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation works to drive medical research, provide survivor support, and promote public awareness and education of the signs, symptoms, and risk factors of ovarian cancer. To that end, the foundation is accepting applications for its 2019 Medical Research Program. Through the program, grants of up to $40,000 will be awarded to investigators working to advance research on ovarian cancer. To be eligible, applicants must be affiliated with a nonprofit institution in the United States.

Tobacco use remains the leading preventable cause of disease and death in the United States. More than half of smokers attempt to quit each year, but fewer than one in ten succeed. Evidence-based cessation treatments, including individual, group, and telephone counseling and seven FDA-approved cessation medications, exist, but are underutilized. The Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health is announcing the opportunity to apply for funds for a competitive, non-research cooperative agreement to provide technical assistance to state tobacco control programs and other partners to translate the science of tobacco control cessation into public health action in order to further increase the rate of cessation among tobacco users in the United States. The funded organizations will accomplish this by providing technical assistance to state tobacco control programs and other partners to 1) Implement health systems change initiatives that seek to integrate tobacco dependence treatment into routine clinical care, including care of persons with behavioral health conditions; and 2) Improve state quitlines' infrastructure, operations, and services to further enhance their effectiveness and efficiency, increase state quitlines' reach, especially among populations experiencing tobacco-related disparities, broaden the range of cessation services offered by state quitlines, and enhance quitline sustainability.

Submit an application if you are a successful top-rank junior researcher from abroad, only completed your doctorate with distinction in the last six years, and have published work in prestigious international journals or publishing houses. The Sofja Kovalevskaja Award allows you to spend five years building up a working group and working on a high-profile, innovative research project of your own choice at a research institution of your own choice in Germany.

The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.

The OCRP Investigator-Initiated Research Award is intended to support high-impact research that has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project.

The OCRP Ovarian Cancer Academy Award mechanism, which was initially created in FY09, is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the Ovarian Cancer Academy (OCA) is to develop successful, highly productive ovarian cancer researchers in a collaborative research and career development environment. The OCA is a virtual career development and research training platform that consists of Early-Career Investigators (ECIs) and their Designated Mentors from different institutions, and an Academy Dean and Assistant Dean. The OCRP Ovarian Cancer Academy - Early-Career Investigator Award is not a traditional career development award; the ECI is expected to participate in monthly webinars and annual workshops and to communicate and collaborate with other members of the Academy (other ECIs, Mentors, Dean, Assistant Dean) as well as with the advocacy community. Since the inception of the Academy, the Academy's ECIs have presented at and chaired sessions for ovarian cancer-specific symposia and served on symposia review committees. They have also served as peer reviewers for the Department of Defense (DoD) OCRP and other funding agencies.